Zecicare-TBR Tablet is a combination pharmaceutical formulation containing Bromelain (90 mg), Trypsin (48 mg), and Rutoside (100 mg), designed to provide anti-inflammatory, proteolytic, and vascular protective effects. Bromelain, a proteolytic enzyme derived from pineapple stems, facilitates the breakdown of proteins, thereby reducing inflammation and edema in various inflammatory conditions. Trypsin, another proteolytic enzyme, complements bromelain by enhancing the degradation of inflammatory mediators and promoting tissue repair. Rutoside, a bioflavonoid, exhibits potent antioxidant properties and strengthens capillary walls, thereby improving microcirculation and reducing capillary permeability. The synergistic action of these components makes Zecicare-TBR effective in managing acute and chronic inflammatory disorders, including post-traumatic swelling, postoperative edema, and venous insufficiency. Additionally, it may be beneficial in conditions characterized by impaired microcirculation and inflammation, such as diabetic microangiopathy and hemorrhoids. The tablet is typically administered orally, with dosage and duration tailored according to clinical indications and patient response. Zecicare-TBR is generally well tolerated, though caution is advised in patients with hypersensitivity to any of its components. It is recommended to use this medication under medical supervision to optimize therapeutic outcomes and monitor for potential adverse effects.